Measurements of absolute CBFmax and rCBFmax in each WHO grade with or without the exclusion of oligodendrogliomas and anaplastic oligodendrogliomas
| Patients/Grades | No. | CBFmax (mL/100 g/min) | rCBFmax | |
|---|---|---|---|---|
| Tumor | Contralateral | |||
| All | ||||
| Grade II | 13 | 85.8 ± 30.3 | 85.3 ± 16.4 | 1.03 ± 0.41 |
| Grade III | 17 | 146.4 ± 84.0b | 80.0 ± 16.1 | 1.81 ± 0.96c |
| Grade IV | 28 | 171.5 ± 58.7d | 77.0 ± 10.9 | 2.25 ± 0.15d |
| Excludeda | ||||
| Grade II | 9 | 75.1 ± 10.4 | 87.7 ± 18.6 | 0.88 ± 0.16 |
| Grade III | 13 | 126.1 ± 74.7e | 80.4 ± 16.6 | 1.52 ± 0.77b |
| Grade IV | 28 | 171.5 ± 58.7d,f | 77.0 ± 10.9 | 2.25 ± 0.15d,g |
↵a With oligodendrogliomas and anaplastic oligodendrogliomas excluded. Note the following P values in each patient group:
↵b P < .05, compared with grade II.
↵c P < .01, compared with grade II.
↵d P < .001, compared with grade II.
↵e P = .05, compared with grade II.
↵f P < .05, compared with grade III.
↵g P < .01, compared with grade III.